Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in the mitral valve prior to taking on his current role where he oversees Abbott's advancements in transcatheter valve technologies.
He explains some of the evolution in the industry as surgical repairs now are offered side-by-side with transcatheter valve replacement and repair technologies. He notes that the number of heart valve patients being treated has increased with the introduction of transcatheter technologies, and that surgical volumes have not been impacted as much as people thing because more patients overall are now being treated for valve disease.
Related Transcatheter Valve Trends Content:
TAVR Expected to See Rapid Growth in Next 5 years
FDA Approves TAVR for Low-risk Patients Creates A Paradigm Shift in Cardiology
VIDEO: The Expansion of TAVR Following the FDA Clearing its Use in All Patients — Interview with Torsten Vahl, M.D.
VIDEO: Overview of the TAVR Program at Tufts Medical Center — Interview with Andrew Weintraub, M.D.
VIDEO: Tracking Transcatheter Valve Outcomes in the STS-ACC TVT Registry — John Carroll, M.D.
VIDEO: Overview of University of Colorado Structural Heart Program — Interview with John Carroll, M.D., Robert Quaife, M.D., and James Chen, Ph.D.
VIDEO: Abbott Structural Heart Technology Advances in 2021 — Interview with Neil Moat, MBBS
Recent Videos View all 619 items
Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability.
The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.
Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies.
Advances she discusses include:
• Leadless pacing and CRT systems
• Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
• Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
• Cryo-ablation balloons.
• Improved EP mapping technologies.
• and left atrial appendage (LAA) occluders.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments.
She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.
Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.
Find more AHA 2021 late-breaking studies and video
Sponsored Videos View all 41 items
With Intellispace Enterprise Edition as the foundation, Philips Healthcare is connecting facilities and service areas within enterprises, while developing standards-based interoperability that preserves customers' investments and best of breed systems.
Perwaiz Meraj, M.D., FACC, FSCAI, director of interventional cardiology, assistant professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health System discusses the importance of hemodynamic support to safely perform a percutaneous coronary intervention (PCI) with prior coronary artery bypass graft (CABG) surgery and comorbidities. Learn more at ProtectedPCI.com/DAIC.
Related Impella Video Content:
VIDEO: Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device — Interview with William O'Neill, M.D.
VIDEO: The Door-to-Unloading (DTU) STEMI Safety and Feasibility Trial — Interview with Navin Kapur, M.D.
VIDEO: Cardiogenic Shock Case with Impella CP Support — Case study with Michael Amponsah, M.D.,
William O'Neill, M.D., highlights best practice protocols based on Impella Quality database and real-world evidence showing improved outcomes in cardiogenic shock. Learn more at ProtectedPCI.com/DAIC
Related Impella Video Content:
VIDEO: Complex PCI Involving Prior CABG and Comorbidities — Interview with Perwaiz Meraj, M.D.
VIDEO: The Door-to-Unloading (DTU) STEMI Safety and Feasibility Trial — Interview with Navin Kapur, M.D.
VIDEO: Cardiogenic Shock Case with Impella CP Support — Case study with Michael Amponsah, M.D.,
Mark Anderson, M.D., FACS, vice chair of cardiac surgery services and cardiothoracic surgeon at Hackensack University Medical Group, outlines a multi-disciplinary heart team approach in treament decision-making for patients in cardiogenic shock. Learn more at ProtectedPCI.com/DAIC.
Anderson discusses improving outcomes for patients in cardiogenic shock through the early use of mechanical circulatory support and the development of a shock protocol with the heart team. He outlines Hackensack University Medical Center’s multi-disciplinary, heart team approach in treatment decision-making for patients in cardiogenic shock. The team includes cardiac surgeons, interventional cardiologists, heart failure specialists and intensivists.
Conference Coverage View all 449 items
Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability.
The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.
Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies.
Advances she discusses include:
• Leadless pacing and CRT systems
• Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
• Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
• Cryo-ablation balloons.
• Improved EP mapping technologies.
• and left atrial appendage (LAA) occluders.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments.
She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.
Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.
Find more AHA 2021 late-breaking studies and video
Cath Lab View all 311 items
Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability.
The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.
Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies.
Advances she discusses include:
• Leadless pacing and CRT systems
• Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
• Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
• Cryo-ablation balloons.
• Improved EP mapping technologies.
• and left atrial appendage (LAA) occluders.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments.
She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.
Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.
Find more AHA 2021 late-breaking studies and video
Cardiac Imaging View all 271 items
Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability.
The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.
Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies.
Advances she discusses include:
• Leadless pacing and CRT systems
• Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
• Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
• Cryo-ablation balloons.
• Improved EP mapping technologies.
• and left atrial appendage (LAA) occluders.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments.
She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.
Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.
Find more AHA 2021 late-breaking studies and video
Cardiac Diagnostics View all 74 items
Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability.
The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.
Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies.
Advances she discusses include:
• Leadless pacing and CRT systems
• Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
• Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
• Cryo-ablation balloons.
• Improved EP mapping technologies.
• and left atrial appendage (LAA) occluders.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments.
She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.
Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.
Find more AHA 2021 late-breaking studies and video
EP Lab View all 82 items
Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability.
The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.
Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies.
Advances she discusses include:
• Leadless pacing and CRT systems
• Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
• Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
• Cryo-ablation balloons.
• Improved EP mapping technologies.
• and left atrial appendage (LAA) occluders.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments.
She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.
Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.
Find more AHA 2021 late-breaking studies and video
Information Technology View all 164 items
Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability.
The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.
Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies.
Advances she discusses include:
• Leadless pacing and CRT systems
• Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
• Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
• Cryo-ablation balloons.
• Improved EP mapping technologies.
• and left atrial appendage (LAA) occluders.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments.
She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.
Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.
Find more AHA 2021 late-breaking studies and video